Literature DB >> 24534531

A TNF-α-CCL20-CCR6 axis regulates Nod1-induced B cell responses.

Maude Paradis1, Barbara C Mindt, Claudia U Duerr, Olga L Rojas, Dennis Ng, Bryant Boulianne, Doug D McCarthy, Mingxi Dennis Yu, Leslie E Summers deLuca, Lesley A Ward, James B Waldron, Dana J Philpott, Jennifer L Gommerman, Jörg H Fritz.   

Abstract

Innate immune responses provoke the accumulation of leukocytes at sites of inflammation. In addition to monocytes and granulocytes, B cells also participate in antimicrobial innate immune responses; however, the mechanisms for accumulation of B cells to sites of inflammation are not well understood. To study B cell accumulation following systemic inflammation, we used a model synthetic ligand that stimulates a specific pattern recognition molecule, nucleotide-binding oligomerization domain-containing protein 1 (Nod1). Upon exposure to Nod1 agonists, both B cells and neutrophils rapidly accumulate within the spleen, and dendritic cells migrate into the periarterial lymphoid sheath. Nod1 stimulation led to a marked increase in several chemokines within the spleen, including CXCL13, CCL2, and CCL20. Whereas the lymphotoxin pathway was critical for the induction of the B cell chemoattractant CXCL13 in response to Nod1 agonists, B cell accumulation within the spleen following Nod1-induced systemic inflammation was independent of the lymphotoxin pathway. In contrast, a CCR6/CCL20 chemokine loop instructed rapid increase of B cells in the spleen in response to systemic administration of Nod1 agonists in a TNF-α-dependent manner. Moreover, CCR6 was required to regulate Nod1-mediated B cell responses. These results reveal a novel mechanism of B cells during inflammation and shed light on how B cells participate in innate immune responses to microbial stimulation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24534531     DOI: 10.4049/jimmunol.1203310

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Association between CCR6 and rheumatoid arthritis: a meta-analysis.

Authors:  Peng Cheng; Ying Zhang; Hui Huang; Weikai Zhang; Qing Yang; Fengjing Guo; Anmin Chen
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis.

Authors:  Adiba I Azad; Anuradha Krishnan; Leia Troop; Ying Li; Tomohiro Katsumi; Kevin Pavelko; Enis Kostallari; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Hepatology       Date:  2020-09       Impact factor: 17.425

3.  TFR Cells Express Functional CCR6 But It Is Dispensable for Their Development and Localization During Splenic Humoral Immune Responses.

Authors:  Cameron R Bastow; Ervin E Kara; Timona S Tyllis; Carola G Vinuesa; Shaun R McColl; Iain Comerford
Journal:  Front Immunol       Date:  2022-06-22       Impact factor: 8.786

Review 4.  Role of chemokine systems in cancer and inflammatory diseases.

Authors:  Hongyi Li; Min Wu; Xia Zhao
Journal:  MedComm (2020)       Date:  2022-06-08

5.  CCR6+ B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis.

Authors:  Huan He; Jianxiong Wu; Mengya Zang; Weihu Wang; Xiuli Chang; Xiangmei Chen; Ruijun Wang; Zhiyuan Wu; Liming Wang; Dongmei Wang; Fengmin Lu; Zongtang Sun; Chunfeng Qu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 6.  Liver specific, systemic and genetic contributors to alcohol-related liver disease progression.

Authors:  Bernd Schnabl; Gavin E Arteel; Felix Stickel; Jan Hengstler; Nachiket Vartak; Ahmed Ghallab; Steven Dooley; Yujia Li; Robert F Schwabe
Journal:  Z Gastroenterol       Date:  2022-01-18       Impact factor: 1.769

7.  MicroRNAs expression profile in CCR6(+) regulatory T cells.

Authors:  Juanjuan Zhao; Yongju Li; Yan Hu; Chao Chen; Ya Zhou; Yijin Tao; Mengmeng Guo; Nalin Qin; Lin Xu
Journal:  PeerJ       Date:  2014-09-18       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.